Tumor markers expression levels in gastric cancer patient's peripheral blood by rt-pcr assessment / Avaliação por rt-pcr de expressão de marcadores tumorais em sangue periférico de pacientes com câncer gástrico

ABSTRACT BACKGROUND: Hematological recurrence is the second most frequent cause of failure in the treatment of gastric cancer. The detection of circulating tumor markers in peripheral blood by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) method may be a useful tool to predict recurrence and determine the patient's prognosis. However, no consensus has been reached regarding the association between the tumor markers level in peripheral blood and its impact on patient survival. AIMS: To evaluate the expression of the circulating tumor markers CK20 and MUC1 in peripheral blood samples from patients with gastric cancer by qRT-PCR, and to verify the association of their expression levels with clinicopathological characteristics and survival. METHODS: A total of 31 patients with gastric adenocarcinoma were prospectively included in this study. CK20 and MUC1 expression levels were analyzed from peripheral blood by the qRT-PCR technique. RESULTS: There was no statistically significant (p>0.05) association between CK20 expression levels and clinical, pathological, and surgical features. Higher MUC1 expression levels were associated with female patients (p=0.01). There was a correlation between both gene levels (R=0.81, p<0.001), and CK20 level and tumor size (R=0.39, p=0.034). CONCLUSIONS: CK20 and MUC1 expression levels could be assessed by qRT-PCR from total peripheral blood samples of patients with gastric cancer. CK20 levels were correlated to MUC1 levels as well as to tumor size. There was no difference in disease-free survival and overall survival regarding both genetic markers expression in this series.

RESUMO RACIONAL: A recorrência hematológica é a segunda causa mais frequente de falha no tratamento do câncer gástrico. A detecção de marcadores tumorais circulantes no sangue periférico, pelo método de reação em cadeia da polimerase de transcrição reversa quantitativa (qRT-PCR) pode ser uma ferramenta útil para prever a recorrência e determinar o prognóstico do paciente. No entanto, ainda não foi alcançado consenso em relação à associação entre o nível de marcadores tumorais circulantes no sangue periférico e seu impacto na sobrevida do paciente. OBJETIVOS: Avaliar a expressão de CK20 e MUC1 em amostras de sangue periférico de pacientes com câncer gástrico por meio de qRT-PCR e verificar a associação dos níveis de expressão com características clinicopatológicas e sobrevida. MÉTODOS: Trinta e um pacientes com adenocarcinoma gástrico foram incluídos, prospectivamente. Os níveis de expressão de CK20 e MUC1 foram analisados a partir de sangue periférico por meio de qRT-PCR. RESULTADOS: Não houve associação estatisticamente significativa (p>0,05) entre os níveis de expressão de CK20 com características clínicas, patológicas e cirúrgicas. Níveis mais elevados de expressão de MUC1 estavam associados a pacientes do sexo feminino (p=0,01). Houve correlação entre os níveis de ambos os genes (R=0,81, p<0,001), nível de CK20 e tamanho do tumor (R=0,39, p=0,034). CONCLUSÕES: Os níveis de CK20 e MUC1 podem ser avaliados por qRT-PCR a partir de amostras de sangue periférico total de pacientes com câncer gástrico, os níveis de CK20 estavam correlacionados com os de MUC1, assim como tamanho do tumor. Não houve diferença de sobrevida global ou livre de doença em relação à expressão de ambos marcadores genéticos nesta série.

French AFU Cancer Committee Guidelines Update 2022-2024: Adrenal tumor - Assessment of an adrenal incidetaloma and oncological management.

INTRODUCTION: The objective of this publication is to recall the initial work-up when faced with an adrenal incidentaloma and, if necessary, to establish the oncological management of an adrenal malignant tumor. MATERIAL AND METHODS: The multidisciplinary working group updated French urological guidelines about oncological assessment of the adrenal incidentaloma, established by the CCAFU in 2020, based on an exhaustive literature review carried out on PubMed. RESULTS: Although the majority of the adrenal masses are benign and non-functional, it is important to investigate them, as a percentage of these can cause serious endocrine diseases or be cancers. Malignant adrenal tumors are mainly represented by adrenocortical carcinomas (ACC), malignant pheochromocytomas (MPC) and adrenal metastases (AM). The malignancy assessment of an adrenal incident includes a complete history, a physical examination, a biochemical/hormonal assessment to look for subclinical hormonal secretion. Diagnostic hypotheses are sometimes available at this stage, but it is the morphological and functional imaging and the histological analysis, which will make it possible to close the malignancy assessment and make the oncological diagnosis. CONCLUSIONS: ACC and MPC are mainly sporadic but a hereditary origin is always possible. ACC is suspected preoperatively but the diagnosis of certainty is histological. The diagnosis of MPC is more delicate and is based on clinic, biology and imagery. The diagnosis of certainty of AM requires a percutaneous biopsy. At the end, the files must be discussed within the COMETE - adrenal cancer network (Appendix 1).

[French ccAFU guidelines - update 2020-2022: malignancy assessment of an adrenal incidentaloma]. / Recommandations françaises du Comité de cancérologie de l'AFU - actualisation 2020-2022 : bilan de malignité d'un incidentalome surrénalien.

INTRODUCTION: - The objective of this publication is to recall the initial oncological management of adrenal incidentalomas. MATERIAL & METHODS: - The multidisciplinary working group updated french urological guidelines established by the CCAFU in 2018, based on an exhaustive literature review carried out on PubMed. RESULTS: - Although the majority of the adrenal masses are benign and non-functional, it is important to investigate them, as a percentage of these can cause serious endocrine diseases or be cancers. Malignant adrenal tumors are mainly represented by Adrenocortical Carcinomas (ACC), malignant pheochromocytomas (MPC) and adrenal metastases (AM). The malignancy assessment of an adrenal incident includes a complete history, a physical examination, a biochemical / hormonal assessment to look for subclinical hormonal secretion. Diagnostic hypotheses are sometimes available at this stage, but it is the morphological and functional imaging and the histological analysis which will make it possible to close the malignancy assessment and make the oncological diagnosis. CONCLUSIONS: - AC and MPC are mainly sporadic but a hereditary origin is always possible. ACC is suspected preoperatively but the diagnosis of certainty is histological. The diagnosis of MPC is more delicate and is based on clinic, biology and imagery. The diagnosis of certainty of AM requires a percutaneous biopsy. At the end, the files must be discussed within the COMETE - adrenal cancer network (Appendix 1).

Avaliação do perfil dos tumores de mama localmente avançados de estadiamento inicial T4N0 no Instituto Nacional de Câncer José Alencar Gomes da Silva / Profile assessment of locally advanced T4N0 breast tumors at the National Cancer Institute José Alencar Gomes da Silva

"Introdução: O câncer de mama localmente avançado é uma forma de apresentação ainda bastante frequente em países em desenvolvimento, correspondendo a um grupo heterogêneo de tumores com comportamento biológico variado. As pacientes são tratadas com abordagem multidisciplinar, incluindo tratamento sistêmico, cirurgia radical e radioterapia. Objetivo: Avaliar se há características presentes em tumores de estadiamento clínico T4N0 que poderiam dar respaldo à realização de biópsia de linfonodo sentinela. Método: Estudo retrospectivo incluindo 50 pacientes com carcinoma invasivo de mama localmente avançado matriculadas no Instituto Nacional de Câncer no período entre fevereiro de 2008 a agosto de 2010. Todas as pacientes foram submetidas a tratamento cirúrgico com mastectomia radical modificada e todas as pacientes foram submetidas à radioterapia adjuvante. Utilizadas variáveis como tamanho do tumor, número de linfonodos acometidos, subtipo molecular e ocorrência de linfedema. Resultados: A média de idade foi 59,42 anos. O tamanho médio do tumor pré-tratamento foi 5,83 cm e pós-tratamento foi 3,2 cm. Terapia neoadjuvante sistêmica foi administrada a 40 pacientes. Trinta e seis casos tinham receptor de estrogênio positivo, 19 pacientes eram receptor de progesterona positivo, 10 pacientes apresentavam HER2 positivo, 5 casos de tumores receptor hormonal negativo e HER2 positivo, 9 pacientes tumores triplo negativos e cinco pacientes com tumores do tipo luminal híbrido. Vinte e três pacientes não apresentaram linfonodos positivos na peça cirúrgica; 18 pacientes apresentaram 1 a 3 linfonodos positivos, 6 pacientes apresentaram de 4 a 9 linfonodos comprometidos e 3 pacientes com 10 ou mais linfonodos comprometidos. Apresentaram linfedema 34% das pacientes, sendo que 41,1% não apresentaram doença axilar na patologia pós-operatória. Das vinte e três pacientes com ausência de doença axilar, 82,6% das pacientes apresentavam, ao exame clínico na triagem, apenas edema cutâneo como característica para classificação T4. Conclusão: A biópsia de linfonodo sentinela poderia ser considerada em casos selecionados de pacientes classificadas como T4b que apresentam como alteração apenas o edema de pele, e com o tratamento sistêmico apresentam resposta terapêutica e resolução completa da alteração cutânea, mantendo-se com axila clinicamente negativa, podendo se beneficiar de um procedimento menos invasivo na axila"(AU)

"Introduction: Locally advanced breast cancer is a form of presentation that is still quite frequent in developing countries, corresponding to a heterogeneous group of tumors with varied biological behavior. Patients are usually treated with a multidisciplinary approach, including systemic treatment, radical surgery and radiation therapy. Objective: To evaluate if there are characteristics present in T4N0 clinical staging tumors that could support the performance of sentinel lymph node biopsy. Method: Retrospective study including 50 patients with locally advanced invasive breast carcinoma enrolled at the National Cancer Institute from February 2008 to August 2010. All patients underwent surgical treatment with modified radical mastectomy and all patients underwent adjuvant radiotherapy. Variables such as tumor size, number of affected lymph nodes, molecular subtype and occurrence of lymphedema were assessed. Results: The average age was 59.42 years. The average size of the pretreatment tumor was 5.83 cm and post-treatment was 3.2 cm. Systemic neoadjuvant therapy was administered to 40 patients. Thirty-six cases had positive estrogen receptor, 19 patients were positive progesterone receptor, 10 patients had HER2 positive, 5 cases of negative hormone receptor and positive HER2 tumors, 9 patients with triple negative tumors and 5 patients with hybrid luminal tumors. 23 patients did not present positive lymph nodes in the surgical specimen; 18 patients had 1 to 3 positive lymph nodes, 6 patients had 4 to 9 compromised lymph nodes and 3 patients with 10 or more compromised lymph nodes. 34% of the patients had lymphedema, and 41.1% of them had no axillary disease in the postoperative pathology. Of the 23 patients with no axillary disease, 82.6% of the patients presented, at screening, on clinical examination, only cutaneous edema as a characteristic for T4 classification. Conclusion: Sentinel lymph node biopsy could be considered in selected cases of patients classified as T4b who present only skin edema as an alteration, and with systemic treatment present therapeutic response and complete resolution of the skin alteration, maintaining a clinically negative armpit and may benefit from a less invasive procedure in the armpit."(AU)

Custo de tratamento do câncer de próstata resistente à castração por meio da aplicação da técnica Delphi no Sistema de Saúde Suplementar brasileiro / Cost of treating castration-resistant prostate cancer by applying the Delphi method to the Brazilian Private Healthcare System

Objetivo: Estimar os custos do tratamento de pacientes com câncer de próstata não metastático resistente à castração (nmCRPC) e metastático resistente à castração (mCRPC) no Sistema de Saúde Suplementar brasileiro. Métodos: Foi realizada uma busca na literatura para avaliar os dados já disponíveis do custo do tratamento do câncer de próstata no Brasil. Como os dados são escassos, optou-se por utilizar a técnica Delphi com seis médicos oncologistas para levantamento do uso dos recursos. O painel Delphi contou com três etapas, sendo duas on-line e uma presencial, abordando recursos, frequência e porcentagem de uso de exames de imagem e laboratoriais, e dados hospitalares (consultas, pronto-socorro, internações ­ clínica, cirúrgica e em unidade de terapia intensiva). Também foram solicitados dados de padrões de tratamento do câncer de próstata. Por fim, dados do manejo das metástases foram requeridos. Por meio das informações coletadas, foi desenvolvido o microcusteio do câncer de próstata resistente à castração na perspectiva do Sistema de Saúde Suplementar. Resultados: O custo total de tratamento da jornada do paciente com câncer de próstata resistente à castração foi igual a 480.497,25 BRL, e o tratamento unicamente da doença não metastática foi de 189.832,79 BRL e o da doença metastática, de 290.664,46 BRL. Conclusão: Os custos do tratamento de câncer de próstata metastático são substancialmente superiores aos custos do tratamento do paciente não metastático resistente à castração de alto risco, o que parece justificar economicamente o uso de medidas que previnam ou adiem o surgimento de metástases.

Objective: To estimate the treatment costs for patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-resistant prostate cancer (mCRPC) within the Brazilian private healthcare system. Methods: A literature search was performed to obtain currently available data on prostate cancer treatment costs in Brazil. As national data are scarce, a Delphi method with a specialist board was chosen with six oncologists for resource estimations. The Delphi panel had three steps: two online and one in-person, addressing what resources, frequencies, and percentages of use of imaging and laboratory exams, hospital data (including medical appointments, emergency room, hospitalizations - clinical, surgical and Intensive Care Unit). Data on prostate cancer treatment patterns were also requested. Finally, metastasis management data was required. Using the collected data, we developed a micro-costing model of castration-resistant prostate cancer in Brazil. Results: The total cost for the entire castration-resistant prostate cancer patient journey was 480.497,25 BRL, with the non-metastatic disease alone costing 189.832,79 BRL and the metastatic disease costing 290.664,46 BRL. Conclusion: The costs of treating metastatic prostate cancer are substantially higher than the treatment of high-risk castration-resistant non-metastatic patients, which seems to economically justify the use of measures that prevent or postpone metastasis.

Câncer de próstata com metástase óssea: impacto econômico para o Sistema de Saúde Suplementar brasileiro / Prostate cancer with bone metastasis: budget impact to the Brazilian Private Heathcare System

Objetivo: O objetivo deste trabalho foi avaliar o impacto de custo total do tratamento de câncer de próstata com metástase óssea na perspectiva do Sistema de Saúde Suplementar (SSS) brasileiro. Métodos: Trata-se de um estudo retrospectivo de coorte conduzido de um banco de dados administrativos fornecidos pela empresa Orizon. A população consistiu em pacientes com registro de câncer de próstata com metástases ósseas, ou procedimentos relacionados, que foram registrados em entradas hospitalares ou ambulatoriais e receberam pelo menos um tipo de tratamento. A perspectiva da análise foi o SSS e o horizonte temporal, uma mediana de 181 dias. O desfecho primário foi o custo global, no qual foram contemplados gastos com exames, procedimentos, materiais e medicamentos. A partir do desfecho primário, foram calculados o custo por paciente, o número de atendimentos por paciente e o custo por atendimento. Adicionalmente foram analisados os custos relacionados aos diferentes subgrupos de tratamentos destinados à doença. Resultados: O custo global relacionado aos atendimentos foi de R$ 21.391.034 (n = 181), o custo médio resultou em R$ 118.183 por paciente, com média de 10,48 atendimentos por paciente e R$ 11.282 por atendimento. Pela análise isolada dos cenários, os custos nos ambientes hospitalar (R$ 11.452.496) e ambulatorial (R$ 9.938.537) demonstraram que houve mais gastos relacionados aos procedimentos hospitalares. Conclusões: O estudo demonstrou elevado impacto econômico de tratamento de câncer de próstata com metástases ósseas no SSS, devido principalmente a maior necessidade de quantidade de hospitalizações com mais tempo de permanência.

Objective: The objective of this study was to evaluate the total cost impact of treatment of prostate cancer with bone metastasis under the Brazilian Private Healthcare System (SSS) perspective. Methods: This is a retrospective cohort study conducted from an administrative database provided by Orizon. The population consisted in patients with prostate cancer with bone metastasis registry, or related procedures, who were registered at hospital or ambulatory admission, and received at least one type of treatment. The perspective of the analysis was SSS and the time horizon was a median of 181 days. The primary outcome was global cost, considering expenses with exams, procedures, materials and drugs. From the primary outcome, cost per patient, number of visits per patient, and visit cost were calculated. Additionally, the costs related to the different subgroups of disease treatments were analyzed. Results: The global cost related to visits was R$ 21,391,034 (n = 181), the average cost resulted in R$ 118,183 per patient, with an average of 10.48 visits per patient and R$ 11,282 per visit. By the isolated analysis of the scenarios, the costs in the hospital (R$ 11,452,496) and ambulatory (R$ 9,938,537) environment demonstrated more expenses related to hospital procedures. Conclusions: The study demonstrated elevated budget impact of prostate cancer with bone metastasis treatment on the SSS, mainly due to greater need for the number of hospitalizations with a longer stay.

Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases.

BACKGROUND: The GETUG 13 phase III trial tested personalised chemotherapy based on tumour marker decline in patients with poor-prognosis germ-cell tumour (GCT) and demonstrated that a dose-dense regimen improves progression-free survival in patients with an unfavourable decline. We investigated the pattern of relapse for patients included in GETUG 13. METHODS: We conducted an analysis of relapse events in patients from GETUG 13. Baseline procedures before inclusion in the trial comprised a thoraco-abdomino-pelvic computed tomography scan and a magnetic resonance imaging of the brain. RESULTS: With a median follow-up of 4.1 years (0.3; 8.8 years), a progression event was observed in 109/254 patients (43%). First event consisted in a marker progression only in 47 patients (43%), a radiographic progression only in 35 patients (32%), a mix progression on both markers and imaging in 12 patients (11%) and death in 15 patients (14%). In patients with radiographic progression only, brain was the predominant site (n = 19/35, 54%). Among patients with unfavourable decline who experienced a radiographic progression (as first and subsequent progression event, n = 58), brain was a site of progression in 28 patients (48%): 12/30 (40%) in patients treated with cisplatin, bleomycin and etoposide and 16/28 (57%) in those treated with dose-dense chemotherapy. CONCLUSIONS: Brain metastases develop often, early and frequently as the only site of relapse in the course of poor-prognosis GCT. This raises the question of early detection and optimal treatment of brain metastases in these patients, e.g. by integrating a systematic brain MRI after 2-3 months of chemotherapy.

[PET scan and NMR spectroscopy for the differential diagnosis between brain radiation necrosis and tumour recurrence after stereotactic irradiation of brain metastases: Place in the decision tree]. / TEP/tomodensitométrie et imagerie spectroscopique par résonance magnétique tridmensionnelle pour le diagnostic différentiel entre radionécrose cérébrale et rechute tumorale après irradiation en conditions stéréotaxiques de métastases cérébrales : place dans l'arbre décisionnel.

PURPOSE: After stereotactic radiation therapy for brain metastases, one of the complications is radionecrosis. Differential diagnosis with tumour recurrence can be helped by different methods of imaging, although histology remains the gold standard. According to the treatment centres, practice diverges. The objective of this single-centre retrospective study was to define the power of MRI, PET scan and NMR spectroscopy to establish a decision tree. MATERIAL AND METHODS: This study included patients who underwent stereotactic radiation therapy for brain metastases, and required, during follow-up, both a PET scan and NMR spectroscopy in order to differentiate a radiation necrosis and tumour recurrence. From 2010 to 2015, 25 patients were consistent with these criteria. RESULTS: Conventional MRI technique, with the T1/T2 mismatch criterion, had a specificity of 75% and a sensitivity of only 44%. A lesion quotient greater than 0.3 diagnosed a recurrence with a sensitivity of 92%. PET scan combined the best sensitivity and specificity, respectively of 92% and 69%. Whatever the thresholds used in NMR spectroscopy for choline/N-acetylaspartate and choline/creatin ratios, the power of this imaging modality did not exceed that of PET scan. CONCLUSION: The criteria described in conventional MRI cannot by themselves establish the differential diagnosis. In first intention in case of doubt, PET scan should be done, combining the best sensitivity and specificity, whereas NMR spectroscopy used in combination does not improve these factors.

Assessment of scores in decision making in metastases of the spine / Avaliação de escores na tomada de decisão em metástases na coluna / Evaluación de las puntuaciones en la toma de decisiones en las metástasis de columna

Objective : The aim of this study is to assess the intra- and interobserver concordance of SINS, Harrington, Tokuhashi and Tomita scores among general orthopedic surgeons and spine surgeons with experience above 5 and 10 years in the evaluation of patients with spinal metastasis. Methods : Twenty cases of patients with metastatic lesion of the spine were presented to 10 examiners and the scores aforementioned have been applied. After six weeks, the cases were reintroduced in a different order and data were analyzed. Results : The intraobserver reliability showed better agreement in SINS score among examiners with less experience and Harrington and Tomita scores among those who had more than 10-year experience. The interobserver reliability of the examiners of the group with over 10-year experience showed higher precision when using these scores, especially Harrington and Tomita. The SINS score was the choice for daily practice and was able to modify the management more often. Conclusions : This study demonstrated that the use of predictive scores of instability, Harrington, and prognosis, Tomita, had a higher intra- and interobserver reliability particularly among spine surgeons with experience above 10 years.

Objetivo : O objetivo deste estudo é avaliar a concordância intra e interobservador dos escores SINS, Harrington, Tokuhashi e Tomita entre ortopedistas gerais e cirurgiões de coluna com experiência acima de cinco e 10 anos na avaliação de pacientes com metástase vertebral. Métodos : Foram apresentados 20 casos de pacientes com lesões metastáticas da coluna vertebral a 10 examinadores e os escores citados acima foram aplicados. Após seis semanas, os casos foram reapresentados em ordem diferente e os dados foram analisados. Resultados : A confiabilidade intraobservador apresentou melhor concordância no escore SINS entre os examinadores com menor experiência, e nos escores de Harrington e Tomita entre os que tinham experiência maior que 10 anos. A confiabilidade interobservador dos examinadores do grupo com experiência maior que 10 anos apresentou maior precisão na utilização desses escores, e com destaque para Harrington e Tomita. O escore SINS foi o de eleição para a prática diária e foi capaz de modificar a conduta com mais frequência. Conclusões : Este estudo demonstrou que o uso de escores preditores de instabilidade, Harrington, e prognóstico, Tomita, apresentam maior confiabilidade intra e interobservador, principalmente entre os cirurgiões de coluna com experiência superior a 10 anos.

Objetivo : El objetivo de este estudio es evaluar la concordancia intra e interobservador en las puntuaciones SINS, Harrington, Tokuhashi y Tomita entre los ortopedistas generales y cirujanos de la columna vertebral con experiencia superior a 5 y 10 años en la evaluación de pacientes con metástasis vertebrales. Métodos : Se presentaron 20 casos de pacientes con lesiones metastásicas de la columna vertebral a 10 examinadores, quienes aplicaron las puntuaciones mencionadas. Luego de seis semanas, los casos fueron reintroducidos en un orden diferente y se analizaron los datos. Resultados : La fiabilidad intraobservador mostró mejor concordancia en la puntuación SINS entre los examinadores con menos experiencia y en los puntajes Harrington y Tomita en los que tenían experiencia de más de 10 años. La fiabilidad interobservador de los examinadores del grupo con más de 10 años de experiencia mostró una mayor precisión en el uso de estas puntuaciones, especialmente las puntuaciones Harrington y Tomita. La puntuación SINS fue de elección para la práctica diaria y ha sido capaz de modificar la conducta con más frecuencia. Conclusiones : Este estudio demostró que el uso de las puntuaciones de predicción de inestabilidad, Harrington, y del pronóstico, Tomita, presentan mayor fiabilidad intra e interobservador principalmente entre los cirujanos de columna con más de 10 años de experiencia.

Avaliação da reprodutibilidade interobservadores de uma nova escala para orientação da conduta terapêutica nas metástases vertebrais: escore SINS (Spine Instability Neoplastic Score) / Assessment of interobserver reproducibility of a new scale for management guidance in spinal metastasis: SINS score / Evaluación de la reproducibilidad interobservador de una nueva escala para la orientación de la conducta terapêutica de las metástasis vertebrales: puntuación SINS

OBJETIVO: Avaliar o impacto na conduta e quantificar a reprodutibilidade interobservador do escore SINS. Além disso, determinar sua aplicabilidade em nosso meio. MÉTODOS: Compilou-se uma apresentação com 20 casos de lesões secundárias da coluna, que foi analisada por 10 observadores. Estes definiram a estabilidade de cada lesão e, após a apresentação do sistema SINS, os mesmos casos foram apresentados aos mesmos observadores para que novamente determinassem a estabilidade da lesão. Os dados colhidos foram analisados por meio do cálculo do Kappa de Fleiss e da correlação intraclasse. RESULTADOS: Obtivemos concordância moderada interobservador com o uso do escore SINS. CONCLUSÕES: O sistema é aplicável em nosso meio. Houve mudança de opinião quanto à estabilidade da lesão após a apresentação do escore aos observadores.

OBJECTIVE: To evaluate the impact on the management and quantify the inter-observer reproducibility of SINS Score. Also, determine its applicability to our milieu. METHODS: A presentation of 20 cases of secondary spine lesions was compiled, which was examined by 10 observers. They defined the stability of each injury and, after the presentation of SINS Score, the same cases were presented to the same observers and again they were asked to determine the stability of the lesion. The collected data were analyzed by the Fleiss' Kappa Calculation and Intra-class Correlation. RESULTS: Inter-observer moderate agreement was obtained by using SINS classification. CONCLUSIONS: The classification is applicable to our milieu. There was a change of opinion about the stability of the lesions after the presentation of the classification to the observers.

OBJETIVO: Evaluar el impacto en la conducta y cuantificar la reproducibilidad interobservador de la escala SINS. Además de eso, determinar la aplicabilidad de la clasificación en nuestro medio. MÉTODOS: Se compiló una presentación de 20 casos de lesiones secundarias de la columna vertebral que fue examinada por 10 observadores. Estos definieron la estabilidad de cada lesión y después de la presentación de la puntuación SINS, los mismos casos fueron presentados a los mismos observadores para que de nuevo determinasen la estabilidad de la lesión. Los datos obtenidos fueron analizados mediante el cálculo de Kappa de Fleiss y de la correlación intraclasse. RESULTADOS: Obtuvimos concordancia moderada interobservador con el uso de la puntuación SINS. CONCLUSIONES: La puntuación es aplicable en nuestro medio. Hubo un cambio de opinión en cuanto a la estabilidad de la lesión después de la presentación de la puntuación a los observadores.